All Oncology News

Replimune completed a Type A meeting with the FDA following a complete response letter for RP1 in advanced melanoma.

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

ISB 2001 had a manageable safety profile and induced deep, durable responses at active doses in patients with relapsed/refractory multiple myeloma.

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

AACR published its annual Cancer Progress Report, outlining advances in cancer treatment and areas for future improvement.

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

Optune Lua plus concurrent PD-1/PD-L1 inhibition has been approved in Japan for advanced non–small cell lung cancer after platinum-based chemotherapy.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Exposure to pollutants, such as pesticides and whildfires, could decrease brain and behavioral function in children, particularly in childhood cancer survivors.

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

Neoadjuvant palbociclib plus endocrine therapy did not improve PEPI scores in operable hormone receptor–positive breast cancer.

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.

T-DXd demonstrated durable systemic and intracranial responses in patients with HER2-positive, -low, and -zero breast cancer brain metastases.

New technology and facility expansions at the Mayo Clinic will soon enable it to treat nearly 75% more patients each year with even more precise and effective therapies.

Ligufalimab has been granted orphan drug designation by the FDA for the treatment of patients with AML.

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

The combination of metformin, letrozole, and abemaciclib was safe and active in patients with ER-positive recurrent endometrial cancer.

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

The Idylla CDx MSI Test will soon be available as a companion diagnostic for identifying patients with MSI-H CRC eligible for treatment with nivolumab.